Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Temozolomide for Recurrent Pituitary Adenomas
NCT03930771Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and temozolomide in pituitary adenoma, sponsored by Weill Cornell Medicine. Primary endpoint: Number of Subjects With Radiographic Response, as Defined by the RECIST Criteria at 6 months. Started May 2019; status: terminated.
02
Drugs
capecitabinetemozolomide
03
Conditions
pituitary adenoma
Beyond the preview
Go deeper on NCT03930771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930771.